GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a net loss, declining cash balances, and potential regulatory and competitive risks. Despite increased revenue from the BARDA contract, the company faces funding challenges and competitive pressures. Management's unclear responses in the Q&A further highlight uncertainties. The positive aspect of strategic partnerships and potential market demand for the Mpox vaccine is overshadowed by these concerns, leading to a negative sentiment.
Key Financial Performance
Revenues $4 million in 2024 (compared to $0 in 2023), an increase of $4 million year-over-year due to the initiation of the BARDA contract in June 2024.
Research and Development Expenses $23.7 million in 2024 (compared to $20.7 million in 2023), an increase of $3 million or 14% year-over-year, primarily due to costs associated with manufacturing clinical trial materials and the BARDA contract.
General and Administrative Expenses $5.4 million in 2024 (compared to $6 million in 2023), a decrease of $600,000 or 11% year-over-year, attributed to lower stock-based compensation, patent costs, and other expenses.
Interest Income $173,000 in 2024 (compared to $776,000 in 2023), a decrease due to lower cash balances.
Net Loss Approximately $25 million in 2024 (compared to $26 million in 2023), a decrease of $1 million year-over-year, primarily driven by manufacturing activities and costs associated with the BARDA contract.
Cash Balances $5.5 million as of December 31, 2024 (compared to $6.5 million in 2023), reflecting $24.7 million used in operating activities.
Outstanding Common Shares 13.9 million shares following recent financing activity.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GEO-CM04S1 Vaccine Development: GeoVax is advancing its next-generation COVID-19 vaccine, GEO-CM04S1, supported by a BARDA Project Next-Gen Award valued at almost $400 million. Manufacturing and support of the vaccine product is underway.
GEO-MVA Vaccine Candidate: GeoVax completed cGMP product and quality release of the clinical batch of GEO-MVA, a vaccine candidate against Mpox and smallpox, with clinical evaluation expected in the second half of 2025.
Gedeptin Trial Plans: Plans for a Phase II Gedeptin trial are underway, focusing on regulatory aspects and product manufacturing.
Mpox Vaccine Supply: GeoVax aims to become the first U.S.-based supplier of the Mpox vaccine, responding to the WHO's declaration of Mpox as a public health emergency.
Government Interest in U.S. Supply Chains: There is increasing government interest in U.S.-based supply chains, which supports GeoVax's position in the market.
Advanced MVA Manufacturing Process: GeoVax is implementing an advanced MVA manufacturing process to produce vaccine material faster and at lower costs.
Partnerships and Collaborations: GeoVax is actively pursuing partnerships and collaborations to support the development and commercialization of its vaccines.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: GeoVax's product candidates will require regulatory approvals necessary to be licensed and marketed, which poses a risk if approvals are not granted.
Competitive Pressures: There is a risk of development of competitive products that may be more effective or easier to use than GeoVax’s products.
Supply Chain Challenges: GeoVax's ability to enter into favorable manufacturing and distribution agreements is uncertain, which could impact product availability.
Funding Needs: GeoVax needs to raise required capital to complete the development of its products, which poses a financial risk.
Market Demand: The ongoing global health threat posed by Mpox and the need for vaccines may create pressure to meet market demand effectively.
Economic Factors: The company faces economic factors that could affect its operations and financial performance, including interest income fluctuations and cash balance management.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
BARDA Project Next-Gen Award: Valued at almost $400 million, supporting GEO-CM04S1, the next-generation COVID-19 vaccine.
GEO-MVA Vaccine Development: Completed cGMP product and quality release of the clinical batch, with clinical evaluation expected in the second half of 2025.
Advanced MVA Manufacturing Process: Anticipated to produce MVA-based vaccine material faster and at reduced costs.
Gedeptin Trial Plans: Clinical operations plans underway for a Phase II trial, focusing on solid tumors.
Strategic Partnerships: Increased activities related to partnering and collaboration for CM04S1.
Mpox Vaccine Positioning: GeoVax aims to be the first U.S.-based supplier of Mpox vaccine, addressing a critical global health need.
Revenue Expectations: Revenues from the BARDA contract were approximately $4 million in 2024, with potential total contract value increasing to $45 million.
Net Loss: Net loss for 2024 was approximately $25 million, or $4.82 per share.
Cash Balances: Cash balances at December 31, 2024 were $5.5 million, down from $6.5 million in 2023.
Funding Strategies: Exploring strategic partnerships, non-dilutive funding, and additional stock offerings to extend cash runway.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Outstanding Common Shares: 13.9 million shares
Net Loss per Share: $4.82 per share
Total Contract Value to GeoVax: $26 million, potentially increasing to $45 million
BARDA Contract Revenues: Approximately $4 million in 2024
Cash Balances: $5.5 million as of December 31, 2024
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you possibly be part of some sort of relatively near-term response by selling product without clinical testing?
A:We don't know, and usually you cannot. But there is opportunity with the latitude of working with WHO through emergency use licensing depending on the recognized need.
Q:How are you working with international partners to ensure equitable vaccine access and manufacturing?
A:We have been in discussions with representatives of Africa's CDC and health ministries in Africa with European colleagues for over a year now, keeping them updated.
Q:What's actually needed to start the next Gedeptin trial? Is that still second quarter ‘25 to start enrollment?
A:We're looking now at probably more into the mid to latter part of next year that we would be initiating the clinical trial.
Q:Could you elaborate on how you're going to test efficacy and safety for MVA?
A:The typical rule has been previously that one dose non-human primates, and we are having discussions with the regulators.
Q:Any estimates at this point as to numbers of patients or endpoints for the clinical trial?
A:We're estimating it's going to probably be in the range of 400 patients or subjects, but that has to be confirmed with the regulators.
Q:How do you think changes in Washington regarding COVID-19 funding might affect the company?
A:We've been receiving that question since probably even before the inauguration. Our discussions with BARDA continue to be positive.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the near-term response to the Mpox threat and the specifics of the Gedeptin trial timeline.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Allucent
American Association
Award
BARDA
CMS potential
CMS vaccine
Capital
GEO CMS
GEO MVA
MVA authority
Mpox Smallpox
Officer PhD
Partners
Phase study
Precision AQ
Project
activity contract
adult
aspect product
benefit
cGMP
candidate Mpox
cost
declaration
expense
gap
health emergency
health threat
plan trial
product support
safety
term
vaccine evaluation
vaccine presentation
vaccine protection
GOVX Transcript
GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call revealed several challenges: declining revenue, increased net losses, and financial instability due to the BARDA contract termination. Despite positive developments in vaccine trials and potential partnerships, the Q&A highlighted concerns over manufacturing, supply chain, and financial vulnerabilities. The lack of clear guidance on critical issues further dampens sentiment. Overall, the negative aspects outweigh the positives, leading to a predicted stock price decline.
GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript
Unknown7-28
The earnings call summary and Q&A reveal mixed sentiments. While the company has strategic partnerships and optimistic plans, the net loss and cash balance raise concerns. The Q&A provided limited clarity on timelines and funding, indicating uncertainties. These factors, alongside a lack of strong financial metrics or guidance, suggest a neutral market reaction.
GeoVax Labs, Inc. (NASDAQ:GOVX) Q1 2025 Earnings Call Transcript
Unknown5-2
The earnings call reveals several negative factors: a Stop Work Order from BARDA, competitive pressures, and supply chain challenges. Although there is an increase in revenue due to the BARDA contract, its termination poses a financial risk. The Q&A section highlights management's lack of clarity on critical issues, further compounding uncertainties. Despite some positive financial metrics, the overall sentiment is negative due to these risks and uncertainties.
GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript
Unknown5-1
The earnings call reveals several negative factors: a Stop Work Order from BARDA, funding challenges, and competitive pressures. While there are some positives, such as increased revenue and no safety issues with the Mpox vaccine, these are overshadowed by regulatory and supply chain risks. The Q&A section highlights management's unclear responses and lack of guidance, further contributing to a negative sentiment. Considering these factors, the stock price is likely to experience a negative movement in the next two weeks.
GOVX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
